AU2001278641A1 - Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof - Google Patents

Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof

Info

Publication number
AU2001278641A1
AU2001278641A1 AU2001278641A AU7864101A AU2001278641A1 AU 2001278641 A1 AU2001278641 A1 AU 2001278641A1 AU 2001278641 A AU2001278641 A AU 2001278641A AU 7864101 A AU7864101 A AU 7864101A AU 2001278641 A1 AU2001278641 A1 AU 2001278641A1
Authority
AU
Australia
Prior art keywords
subtype
isolates
hiv
genes
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278641A
Inventor
Robert Edward Johnston
Salim Abdool Karim
Lynn Morris
Ronald Ivar Swanstrom
Carolyn Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
University of North Carolina at Chapel Hill
Alphavax Inc
University of Cape Town
Original Assignee
Medical Research Council
University of North Carolina at Chapel Hill
Alphavax Inc
University of North Carolina System
University of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, University of North Carolina at Chapel Hill, Alphavax Inc, University of North Carolina System, University of Cape Town filed Critical Medical Research Council
Publication of AU2001278641A1 publication Critical patent/AU2001278641A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AU2001278641A 2000-07-07 2001-07-09 Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof Abandoned AU2001278641A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21699500P 2000-07-07 2000-07-07
US60/216,995 2000-07-07
ZA2000/3437 2000-07-10
ZA200003437 2000-07-10
ZA2000/4924 2000-09-15
ZA200004924 2000-09-15
PCT/IB2001/001208 WO2002004494A2 (en) 2000-07-07 2001-07-09 Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof

Publications (1)

Publication Number Publication Date
AU2001278641A1 true AU2001278641A1 (en) 2002-01-21

Family

ID=27396355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278641A Abandoned AU2001278641A1 (en) 2000-07-07 2001-07-09 Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof

Country Status (5)

Country Link
EP (1) EP1309617B1 (en)
CN (1) CN1547587A (en)
AP (1) AP2005A (en)
AU (1) AU2001278641A1 (en)
WO (1) WO2002004494A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910716B2 (en) 2000-07-07 2011-03-22 Medical Research Council Nucleic acids encoding modified South African HIV-1 subtype C gag proteins
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7479547B2 (en) 2001-10-31 2009-01-20 The South African Medical Research Council HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof
AP2005003338A0 (en) * 2002-12-04 2005-06-30 Univ Cape Town And South Afric A method for production of HIV-1 Gag virus-like particles

Also Published As

Publication number Publication date
CN1547587A (en) 2004-11-17
WO2002004494A3 (en) 2003-03-13
AP2005A (en) 2009-06-10
EP1309617A2 (en) 2003-05-14
AP2003002733A0 (en) 2003-03-31
WO2002004494A2 (en) 2002-01-17
EP1309617B1 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
AU2001241068A1 (en) Indole derivatives, process for preparation of the same and use thereof
AU2003233010A1 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
IL158289A (en) Mercaptoacetylamide derivatives, a process for their preparation and their use as medicaments for the treatment of hypertension and chf
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
HK1061021A1 (en) Pyrazole derivatives for the treatment of viral diseases.
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
AU2001241056A1 (en) Spiro compounds, process for preparing the same and use thereof as drugs
AU2001294228A1 (en) Benzimidazole compounds, process for producing the same and use thereof
AU2001229525A1 (en) Direct epoxidation process using improved catalyst composition
AU2002214157A1 (en) Polymerisation process
AU5426500A (en) Benzazepine derivatives, process for the preparation of the same and uses thereof
AU2001273762A1 (en) Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
AU2001242795A1 (en) Condensed pyrazole derivatives, process for producing the same and use thereof
AU6866500A (en) Chromone derivatives, process for the preparation of the same and uses thereof
AU2001278641A1 (en) Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof
AU4617600A (en) A process for preparing xanthorrizol from LTiGTcurcuma xanthorrizaLT/iGT roxb. and novel uses of the same
HK1042092A1 (en) Novel morpholine derivatives, method for the prod uction thereof and pharmaceutical preparations containing said derivatives.
AP2008004393A0 (en) Process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereog
AU6870500A (en) Process for the preparation of 2,3-dihydroazepine derivatives
AU2002363189A1 (en) Hiv-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof
AU2000261768A1 (en) An improved process for the preparation of docetaxel
MXPA03004454A (en) Imidazolone derivatives for the treatment of viral diseases.
ZA200101529B (en) Process for the preparation of isoindoline.
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
AU2002229149A1 (en) Process for producing hydrazinomonosaccharide derivatives and use thereof